FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1485772655> ?p ?o ?g. }

• W1485772655 endingPage "712" @default.
• W1485772655 startingPage "703" @default.
• W1485772655 abstract "This study evaluated the effects of impaired renal function on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban (10mg single dose), an oral, direct Factor Xa inhibitor.Subjects (n= 32) were stratified based on measured creatinine clearance: healthy controls (≥80ml min(-1) ), mild (50-79mlmin(-1) ), moderate (30-49mlmin(-1) ) and severe impairment (<30mlmin(-1) ).Renal clearance of rivaroxaban decreased with increasing renal impairment. Thus, plasma concentrations increased and area under the plasma concentration-time curve (AUC) LS-mean values were 1.44-fold (90% confidence interval [CI] 1.1, 1.9; mild), 1.52-fold (90% CI 1.2, 2.0; moderate) and 1.64-fold (90% CI 1.2, 2.2; severe impairment) higher than in healthy controls. Corresponding values for the LS-mean of the AUC for prolongation of prothrombin time were 1.33-fold (90% CI 0.92, 1.92; mild), 2.16-fold (90% CI 1.51, 3.10 moderate) and 2.44-fold (90% CI 1.70, 3.49 severe) higher than in healthy subjects, respectively. Likewise, the LS-mean of the AUC for Factor Xa inhibition in subjects with mild renal impairment was 1.50-fold (90% CI 1.07, 2.10) higher than in healthy subjects. In subjects with moderate and severe renal impairment, the increase was 1.86-fold (90% CI 1.34, 2.59) and 2.0-fold (90% CI 1.44, 2.78) higher than in healthy subjects, respectively.Rivaroxaban clearance is decreased with increasing renal impairment, leading to increased plasma exposure and pharmacodynamic effects, as expected for a partially renally excreted drug. However, the influence of renal function on rivaroxaban clearance was moderate, even in subjects with severe renal impairment." @default.
• W1485772655 created "2016-06-24" @default.
• W1485772655 creator A5008273708 @default.
• W1485772655 creator A5009158219 @default.
• W1485772655 creator A5028242817 @default.
• W1485772655 creator A5029996821 @default.
• W1485772655 creator A5030589596 @default.
• W1485772655 creator A5040870075 @default.
• W1485772655 creator A5042838066 @default.
• W1485772655 creator A5063405482 @default.
• W1485772655 creator A5075888206 @default.
• W1485772655 creator A5085514176 @default.
• W1485772655 date "2010-07-15" @default.
• W1485772655 modified "2023-09-27" @default.
• W1485772655 title "Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor" @default.
• W1485772655 cites W1969218311 @default.
• W1485772655 cites W1980669153 @default.
• W1485772655 cites W1983727955 @default.
• W1485772655 cites W1989930316 @default.
• W1485772655 cites W2014491911 @default.
• W1485772655 cites W2021621876 @default.
• W1485772655 cites W2022932023 @default.
• W1485772655 cites W2028162842 @default.
• W1485772655 cites W2028762958 @default.
• W1485772655 cites W2034365627 @default.
• W1485772655 cites W2036506340 @default.
• W1485772655 cites W2045987573 @default.
• W1485772655 cites W2050900880 @default.
• W1485772655 cites W2053571003 @default.
• W1485772655 cites W2057065644 @default.
• W1485772655 cites W2060578439 @default.
• W1485772655 cites W2066676409 @default.
• W1485772655 cites W2075359369 @default.
• W1485772655 cites W2115513773 @default.
• W1485772655 cites W2116489124 @default.
• W1485772655 cites W2120108153 @default.
• W1485772655 cites W2123858403 @default.
• W1485772655 cites W2143986922 @default.
• W1485772655 cites W2150567120 @default.
• W1485772655 cites W2151252098 @default.
• W1485772655 cites W2491061016 @default.
• W1485772655 cites W4322696768 @default.
• W1485772655 doi "https://doi.org/10.1111/j.1365-2125.2010.03753.x" @default.
• W1485772655 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2997310" @default.
• W1485772655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21039764" @default.
• W1485772655 hasPublicationYear "2010" @default.
• W1485772655 type Work @default.
• W1485772655 sameAs 1485772655 @default.
• W1485772655 citedByCount "365" @default.
• W1485772655 countsByYear W14857726552012 @default.
• W1485772655 countsByYear W14857726552013 @default.
• W1485772655 countsByYear W14857726552014 @default.
• W1485772655 countsByYear W14857726552015 @default.
• W1485772655 countsByYear W14857726552016 @default.
• W1485772655 countsByYear W14857726552017 @default.
• W1485772655 countsByYear W14857726552018 @default.
• W1485772655 countsByYear W14857726552019 @default.
• W1485772655 countsByYear W14857726552020 @default.
• W1485772655 countsByYear W14857726552021 @default.
• W1485772655 countsByYear W14857726552022 @default.
• W1485772655 countsByYear W14857726552023 @default.
• W1485772655 crossrefType "journal-article" @default.
• W1485772655 hasAuthorship W1485772655A5008273708 @default.
• W1485772655 hasAuthorship W1485772655A5009158219 @default.
• W1485772655 hasAuthorship W1485772655A5028242817 @default.
• W1485772655 hasAuthorship W1485772655A5029996821 @default.
• W1485772655 hasAuthorship W1485772655A5030589596 @default.
• W1485772655 hasAuthorship W1485772655A5040870075 @default.
• W1485772655 hasAuthorship W1485772655A5042838066 @default.
• W1485772655 hasAuthorship W1485772655A5063405482 @default.
• W1485772655 hasAuthorship W1485772655A5075888206 @default.
• W1485772655 hasAuthorship W1485772655A5085514176 @default.
• W1485772655 hasBestOaLocation W14857726552 @default.
• W1485772655 hasConcept C111113717 @default.
• W1485772655 hasConcept C112705442 @default.
• W1485772655 hasConcept C126322002 @default.
• W1485772655 hasConcept C126894567 @default.
• W1485772655 hasConcept C159641895 @default.
• W1485772655 hasConcept C2776301958 @default.
• W1485772655 hasConcept C2778661090 @default.
• W1485772655 hasConcept C2779161974 @default.
• W1485772655 hasConcept C2780306776 @default.
• W1485772655 hasConcept C2780434524 @default.
• W1485772655 hasConcept C71924100 @default.
• W1485772655 hasConcept C76318530 @default.
• W1485772655 hasConcept C90924648 @default.
• W1485772655 hasConceptScore W1485772655C111113717 @default.
• W1485772655 hasConceptScore W1485772655C112705442 @default.
• W1485772655 hasConceptScore W1485772655C126322002 @default.
• W1485772655 hasConceptScore W1485772655C126894567 @default.
• W1485772655 hasConceptScore W1485772655C159641895 @default.
• W1485772655 hasConceptScore W1485772655C2776301958 @default.
• W1485772655 hasConceptScore W1485772655C2778661090 @default.
• W1485772655 hasConceptScore W1485772655C2779161974 @default.
• W1485772655 hasConceptScore W1485772655C2780306776 @default.
• W1485772655 hasConceptScore W1485772655C2780434524 @default.
• W1485772655 hasConceptScore W1485772655C71924100 @default.
• W1485772655 hasConceptScore W1485772655C76318530 @default.

• next